Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene EML4 NTRK3
Variant EML4 - NTRK3
Impact List fusion
Protein Effect gain of function
Gene Variant Descriptions EML4-NTRK3 results from the fusion of EML4 and NTRK3 and leads to transformation of cultured cells and activation of MAPK signaling in a reporter assay (PMID: 30279230). EML4-NTRK3 has been identified in MSI-high colorectal cancer (PMID: 30279230).
Associated Drug Resistance

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
EML4 - NTRK3 thyroid gland papillary carcinoma predicted - sensitive Entrectinib Case Reports/Case Series Actionable In a clinical case study, a patient with papillary thyroid carcinoma harboring EML4-NTRK3 demonstrated a 69.7% decrease in disease burden after 34 cycles of treatment with Rozlytrek (entrectinib) (PMID: 32457407). 32457407
EML4 - NTRK3 malignant glioma predicted - sensitive Crizotinib Preclinical - Cell culture Actionable In a preclinical study, treatment with Xalkori (crizotinib) resulted in inhibition of cell growth in a glioma cell line harboring EML4-NTRK3 in culture (PMID: 25485619). 25485619
EML4 - NTRK3 Advanced Solid Tumor predicted - sensitive Entrectinib Case Reports/Case Series Actionable In a Phase Ib/II trial (STARTRK-NG), a patient with an advanced solid tumor harboring EML4-NTRK3 demonstrated a partial response when treated with Rozlytrek (entrectinib) (Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 107-107; NCT02650401). detail...
EML4 - NTRK3 Advanced Solid Tumor predicted - sensitive Entrectinib Preclinical - Cell culture Actionable In a preclinical study, Rozlytrek (entrectinib) inhibited growth of transformed cells expressing EML4-NTRK3 in culture (PMID: 30279230). 30279230
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Molecular Profile Protein Effect Treatment Approaches
EML4 - NTRK3 gain of function Larotrectinib